

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/009,151	04/16/2002	Takashi Shigematsu	13723-002001 8643		
26161 7590 02/09/2007 FISH & RICHARDSON PC P.O. BOX 1022			EXAMINER		
			LUM, LEON YUN BON		
MINNEAPOL	IS, MN 55440-1022		ART UNIT	PAPER NUMBER	
			1641		
			MAIL DATE	DELIVERY MODE	
			02/09/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

31 6 X

Application No.	Applicant(s)		
10/009,151	SHIGEMATSU ET AL.		
Examiner	Art Unit	_	
Leon Y. Lum	1641		

3 ,,,	LAGIIIIIIEI	Aitonit	
	Leon Y. Lum	1641	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>12 January 2007</u> FAILS TO PLACE THIS A	APPLICATION IN CONDITION FOR	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	n the same day as filing a Notice of wing replies: (1) an amendment, aff otice of Appeal (with appeal fee) in o	Appeal. To avoid aba idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) \square The period for reply expires $\underline{5}$ months from the mailing date	•		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire			
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7		FIRST REPLY WAS F	ILED WITHIN
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 dension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The approprinally set in the final Off	iate extension fee ice action; or (2) as
 The Notice of Appeal was filed on A brief in complifing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed. 	ension thereof (37 CFR 41.37(e)), to	avoid dismissal of th	
AMENDMENTS 3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	will not be entered b	ACSUSA
(a) They raise new issues that would require further co			ccause
(b) They raise the issue of new matter (see NOTE belo	,	, ,	
(c) They are not deemed to place the application in be appeal; and/or		ducing or simplifying	the issues for
(d) They present additional claims without canceling a		ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. \square The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).
Applicant's reply has overcome the following rejection(s			
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 	·	·	
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		ll be entered and an	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good ar was not earlier presented. See 37 CFR 1.116(e). 	ut before or on the date of filing a N nd sufficient reasons why the affidat	otice of Appeal will <u>n</u> vit or other evidence i	ot be entered s necessary and
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar 	overcome <u>all</u> rejections under appe ry and was not earlier presented. S	al and/or appellant fa see 37 CFR 41.33(d)(ils to provide a 1).
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	ntry is below or attac	hed.
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application i	n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s).	å	
13. Other:	(1	
		LONG V. Supervisory patei	
		OUTENVIOURT PAIL	NI EXAMINER

TECHNOLOGY CENTER 1600

Continuation of 11. does NOT place the application in condition for allowance because of the reasons set forth in the previous Office Action. The response After Final filed on January 12, 2007 did not include claim amendments, but provided arguments traversing the rejections made in the previous Office Action. Specifically, Applicants argue several points:

- (1) Applicants contend that the combination of Proksch (US 4,216,117) with each of Kamarei (US 4,217,117) and Magneson (US 5,547,873) does not teach the claimed invention because Proksch teaches determining amounts of cholesterol and triglyceride, and such compounds are not lipoproteins. See page 10, 3rd-4th paragraphs and page 13, 5th full paragraph.
- (2) Applicants argue that the Examiner is "picking and choosing" the freeze-thaw treatment and freeze-drying steps out of a "laundry list" of 26 disclosed steps. See pages 10-13, especially page 12, 2nd paragraph.
- (3) Applicants argue that since Magneson discloses that the proteins are recovered in their native structures, they cannot teach the denatured proteins of the claimed invention. See page 14, the entire page.

Applicants' arguments have been fully considered, but are not convincing and do not overcome the applied rejections.

Regarding Applicants' argument (1) above, Proksch teaches a lipoprotein diluent having lipoproteins therein. While Applicants correctly p oint out that Proksch explicitly describes the measurement of cholesterol and triglyceride, it is noted that these compounds make up the lipid portion of lipoproteins, which are protein-lipid compounds. Therefore, by detecting the "part" of cholesterol and triglyceride, the "whole" of lipoproteins are necessarily detected.

Regarding Applicant's argument (2) above, Applicants cite In re Fine, 5 USPQ 2d 1596-1600 (Fed. Cir. 1988) in supporting their claim that the Examiner was "picking and choosing." The specific portion of the case cited is the phrase "[o]ne cannot use hindsight reconstruction to pick and choose among isolated disclosure in the prior art to depreceate the claimed invention." See page 12, 2nd full paragraph of the Arguments. In re Fine was a decision rendered by the Court of Appeals for the Federal Circuit which held that the Examiner's application of an obvious rejection was improper because there was no explicit reason to combine the primary and secondary references, other than an "obvious to try" rationale. Id at 1600. The court concluded that the Examiner had engaged in improper hindsight reconstruction by "picking and choosing" an isolated secondary reference to teach a limitation the primary reference was lacking. Id. The case therefore hinged on the fact that the "picking and choosing" was performed in the entire prior art to select one reference to combine with another reference. However, Applicants' case here is different and distinguished from In re Fine. The two steps in question, the "freeze-thaw treatment" and "freeze-drying," were not in separate references, but disclosed in one reference (i.e. Kamarei). Furthermore, in the same paragraph in which Kamarei discloses the two freezing steps, Kamarei also explicitly teaches that "any combination of more than one of the above methods" is applicable. See Kamarei, column 8, lines 51-52. Therefore, Kamarei explicitly teaches that the freezedrying and freeze-thaw treatment can be combined to produce one method with two freezing steps in succession. Although the two freezing steps are among a plurality of different treatments that can be chosen in combination, the mere fact that there is a plurality of steps to choose from does not implicate improper hindsight, especially since the reference itself discloses that different treatment methods can be combined. Applicants have also traversed the Examiner's conclusion that in combining the freeze-thaw and freeze-drying steps, that the freeze-drying must be performed after the freeze-thaw treatment. Applicants argue that it would be possible to dissolve the freeze-dried products in order to perform a freeze-thaw treatment. However, this assumption requires that such a dissolving step be inserted. Such a step is not cited in the rejection, which relies on Kamarei for just the freeze-thaw and freeze-drying treatements. Therefore, in combining these steps, it would be necessary to perform the freeze-thaw treatment first, since the freeze-drying step removes all liquid and would therefore prevent subsequent freeze-thawing.

Regarding Applicants' argument (3) above, the patentable weight of the instant claims is the active method steps claimed. Since Magneson teaches the same steps, as described in the previous Office Action, the claims are taught in the prior art. Since the instant claims having open language (i.e. "comprising"), they leave open the ability for a prior art reference to teach the claimed language even if it includes additional steps not recited by the instant claims. Therefore, although Magneson teaches reconstituted proteins that retain their native structure, this does not per se negate the reference's application against the instant claims of a denatured protein structure due to (1) the open "comprising" language and (2) the fact that Magneson teaches each and every claimed step.

Leon Y. Lum Patent Examiner Art Unit 1641 (571) 272-2878